Heart transplant from organ donor with hepatitis C associated with decreased survivalOctober 18, 2006Heart transplant patients who receive a donor heart from a person with hepatitis C have a lower rate of survival, according to a study in the October 18 issue of JAMA. A shortage of cardiac organ donors results in a substantial number of deaths among persons awaiting cardiac transplantation. One potential approach for increasing the availability of donors is to broaden the criteria used to identify appropriate donors. For example, the cardiac donor pool could be expanded by using donors with hepatitis C virus (HCV) infection. Hearts from donors infected with HCV carry a substantial risk of transmission of HCV to the recipient, and high rates of subsequent liver enzyme abnormalities have been observed, according to background information in the article. The effect on patient survival has not been clear. Leanne B. Gasink, M.D., M.S.C.E., of the University of Pennsylvania School of Medicine, Philadelphia, and colleagues conducted a study to determine the relationship between donor HCV status and survival in cardiac transplant recipients. The study included data from the Scientific Registry of Transplant Recipients. Adult heart transplant patients who received their transplants between April 1994 and July 2003 were eligible for inclusion. Of 10,915 patients meeting entry criteria, 261 received an HCV-positive donor heart. The researchers found that the rate of death was higher among recipients of hearts from HCV-positive donors compared with recipients of hearts from HCV-negative donors at 1 year (16.9 percent vs. 8.2 percent), 5 years (41.8 percent vs. 18.5 percent), and 10 years (50.6 percent vs. 24.3 percent). At 1, 5, and 10 years, survival rates were 83 percent, 53 percent, and 25 percent for recipients of HCV-positive donor hearts, and 92 percent, 77 percent, and 53 percent for recipients of HCV-negative donor hearts, respectively. This association appears to be independent of recipient HCV status and age. Recipients of HCV-positive donor hearts were more likely to die of liver disease and coronary vasculopathy (disease of the coronary arteries). "Preferential allocation of HCV-positive donors to HCV-positive recipients and/or older recipients is not warranted," the authors conclude. JAMA and Archives Journals |
|||||||||||||||||||||
| Related Hepatitis C Current Events and Hepatitis C News Articles Mount Sinai finds those with more difficult to treat forms of HCV are half as likely to get treated A new study by Mount Sinai researchers has for the first time found that patients with more difficult to treat forms of hepatitis C are half as likely to initiate treatment for the disease, when compared to patients with hepatitis C that is easier to treat. Extending treatment after liver transplant may benefit patients with hepatitis C recurrence Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study. Discovery could improve hepatitis C treatment Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments. Genetic hint for ridding the body of hepatitis C More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. Men experience sexual dysfunction during hepatitis C therapy Sexual impairment is common among men with chronic hepatitis C undergoing antiviral therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. Is endotoxin receptor CD14 rs2569190/C-159T gene correlated with chronic hepatitis C? It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Hepatitis C virus channels efforts into cell survival Researchers at the University of Leeds have discovered a previously unknown mechanism that allows the hepatitis C virus (HCV) to remain in the body for decades. New Strategy for Inhibiting Virus Replication Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication. New biomarker predicts response to hepatitis C treatment Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference. The hepatitis healing power of blueberry leaves A chemical found in blueberry leaves has shown a strong effect in blocking the replication of the Hepatitis C virus, opening up a new avenue for treating chronic HCV infections, which affect 200 million people worldwide and can eventually lead to cirrhosis and liver cancer. More Hepatitis C Current Events and Hepatitis C News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||